Mi-Yeong Kim, MD
,
Internal Medicine, Seoul National Univesity College of Medicine, Seoul, South Korea
Min-Hye Kim
,
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
Woo Kyung Kim, MD, PhD
,
Asthma & Allergy, Dongguk University Ilsan Hospital, Goyang, South Korea
Sae-Hoon Kim
,
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
Sun-Sin Kim
,
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
Woo-Jung Song
,
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
Heung-Woo Park
,
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
Jae-Woo Kwon
,
Internal Medicine, Kangwon National University, Choonchun, South Korea
Min-Suk Yang, MD
,
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
Jae-Woo Jung
,
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
Keun-Wook Lee
,
Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
Sang-Heon Cho
,
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
Kyung-Up Min
,
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
You-Young Kim, MD, PhD
,
Department of Internal medicine, division of allergy and clinical immunology, National Medical Center, Seoul, South Korea
Jee Hyun Kim, MD, PhD
,
Seoul National Univesity College of Medicine, Seongnam, South Korea
Yoon-Seok Chang, MD, PhD
,
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
Background:
Oxaliplatin hypersensitivity is one of well-known hypersensitivity reactions but the incidence varies. The incidence and clinical features has not been reported in Korea. There are few reports on the risk factors of oxaliplatin hypersensitivity. We report the 1-year incidence of hypersensitivity to oxaliplatin in our clinical program, and the characteristics of the patients and diseases associated with its occurrence. This is the first report on the incidence of oxaliplatin hypersensitivity in Korea.
Methods:
Clinical information on all patients treated with oxaliplatin between August 2009 and July 2010 in Seoul National University Bundang Hosptial was retrospectively reviewed. Data from the patients who experienced hypersensitivity were compared with those who did not.
Results:
Total of 393 patients received oxaliplatin, with 42 experiencing hypersensitivity. Incidence was 10.7%. Median of first hypersensitivity event was 8. Most frequent symptom was urticaria and rash (71.4%). There were three cases of anaphylaxis (7.1%). Most patients (384, 97.7%) received premedication including dexamethasone. Two patients with hypersensitivity were successfully treated with oxaliplatin by desensitization. Hypersensitivity was correlated with lower dexamathasone dose. However other variables were not significant in our study.
Conclusions:
The incidence of hypersensitivity to oxaliplatin was 10.7%. Most common symptom was cutanenous presentation. Oxaliplatin could induce anaphylaxis. We found lower dexamathasone dose to be predictor for reactions.
